There is one clinical trial.
Predi-COVID is a prospective cohort study composed of people positively tested for COVID-19 in Luxembourg, followed digitally for monitoring participants' health evolution and symptoms at home. Participants will be actively followed for 14 days from the time of confirmation of diagnosis, whether they are at the hospital or at home in isolation or quarantine. Short evaluations will be also performed at week 3 and week 4 and then monthly for a period up to 12 months to assess potential long term consequences of COVID-19. A subsample of 200 participants will be contacted to integrate complementary clinical data and collect samples. The study aims at identifying factors associated with the COVID-19 disease severity. COVID-19 patients with severity criteria will be compared to patients with mild disease managed at home. A deep phenotyping related to the symptoms of the disease as well as biosampling allowing for laboratory-based and computational analytics will be performed.
Description: Number of symptoms associated with Covid-19Measure: Description of clinical manifestations Time: 1 year
Description: Number of hospitalizationsMeasure: Clinical aggravation of the infection Time: 1 year
Description: Number of dischargesMeasure: Discharge of hospitalization Time: 1 year
Description: Number of deathsMeasure: Death Time: 1 year
Description: Whole blood count parametersMeasure: Description of biological manifestations Time: 1 year
Description: Plasma cytokine levelsMeasure: Description of biological manifestations Time: 1 year
Description: Antibodies to SARS-Cov2Measure: Description of biological manifestations Time: 1 year
Description: HLA genotypesMeasure: Patient-related prognostic factors Time: 1 year
Description: CoinfectionsMeasure: Patient-related prognostic factors Time: 1 year
Description: Virus mutationsMeasure: Virus-related prognostic factors Time: 1 year
Description: Audio feature extracted from 30 seconds recordings of participants' voice reading a prespecified text, collected throughout the CoLIVE LIH smartphone app.Measure: Vocal biomarker of Covid-19 related respiratory complications Time: 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports